SECURING THE Lu-177 SUPPLY CHAIN
An established therapeutic isotope that emits beta-radiation, Lu-177 efficiently kills nearby cancer cells when labelled to a cancer-seeking molecule. With over 100 clinical trials and the emergence of at least two billion dollar Lu-177 cancer treatments in recent years, the supply chain for Ytterbium-176 is under immense pressure with traditional Russian sources no longer viable.
Advancing Radiopharmaceutical Production in South Australia
IsoMedica is able to produce Yb-176 at higher levels of purity than most market competitors, reducing issues with reactor operators to produce Lu-177 and thus, is in greater demand from end users. Our isotope purification process has much lower capital costs than competitors. With support from the South Australian Government through the Economic Recovery Grant, IsoMedica will scale up the existing lab scale project into the new Advanced Radioisotope Production Facility (ARPF) South Australia.
OTher Projects